688192 Dizal Pharmaceutical
- 37.50
- -0.15-0.40%
Dizal Pharmaceutical News
Dizhe Pharmaceutical: Announcement of Resolutions of the Seventh Meeting of the 2nd Board of Supervisors
Dizhe Pharmaceutical: Special Report on the Storage and Actual Use of Funds Raised for the 2024 Semi-Annual Year
Dizhe Pharmaceutical: Semi-annual Evaluation Report on the 2024 “Improve Quality, Increase Efficiency, and Value Return” Action Plan
Dizhe Pharmaceutical: Announcement of Resolutions of the Eighth Meeting of the 2nd Board of Directors
Dizhe Pharmaceutical: Report on the use of previously raised funds
Dizhe Pharmaceutical: Announcement on the change of accounting firm
Dighe (Jiangsu) Pharmaceutical Co., Ltd. Investor Relations Activity Record Form from April to May 2024
Digel Pharmaceutical Investor Relations Activity Record Table_2023 Pharmaceutical Special Group Performance Briefing
Dizal: Announcement on attending the 2023 Science and Technology Innovation Board Pharmaceutical Special Performance Briefing
Dizal: Huatai United Securities Co., Ltd.'s 2023 Continuous Supervision and Follow-up Report on Dighe (Jiangsu) Pharmaceutical Co., Ltd.
Dizal: 2023 Financial Statements and Audit Report
Dizal: PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership) Report and Verification Report on the Use of Funds Raised by Digee (Jiangsu) Pharmaceutical Co., Ltd. as of December 31, 2023
Dizal: Report on the use of previously raised funds
Dizal: PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership) Special Report on the Capital Occupation by the Controlling Shareholders and Other Related Parties of Digee (Jiangsu) Pharmaceutical Co., Ltd. in 2023
Dizal: Announcement on Using Part of the Overraised Capital to Permanently Replenish Liquidity and Fund Raised Wealth Management Proceeds and Interest for Fund-raising Projects
Dizal: Huatai United Securities Co., Ltd.'s verification opinion on Dighe (Jiangsu) Pharmaceutical Co., Ltd.'s use of part of the overfunded capital to permanently supplement working capital and financial management income and interest
Dizal: Announcement on the implementation status of daily transactions in 2023 and the forecast for daily related transactions in 2024
Dizal: Huatai United Securities Co., Ltd.'s inspection opinions on the implementation status of Dizhe (Jiangsu) Pharmaceutical Co., Ltd.'s 2023 daily related transactions and the forecast for 2024 daily related transactions
Dizal: 2023 Independent Director Debriefing Report-Jiang Bin
Dizal: PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership) on the 2023 Internal Control Audit Report of Digee (Jiangsu) Pharmaceutical Co., Ltd.
Analysis
Price Target
No Data
